Obesity and type 2 diabetes mellitus (T2DM) is reaching pandemic levels, but there are still only a few anti-obesity drugs available. In the review, researchers led by Lenka Maletínská from IOCB Prague together with colleagues from the Institute of Physiology summarize the preclinical results of their chronic studies of the two most potential palmitoylated anorexigenic peptides analogs in various mouse and rat models of obesity, glucose intolerance, and insulin resistance.
Anorexigenic peptides are involved in food intake and body weight regulation. Their palmitoylated analogs show high binding affinities, increased stability, and central anorexigenic effects after peripheral administration, as well as body weight and glucose lowering effects thus having the potential to be an attractive candidate for obesity therapy.
Read the article:
- Mráziková, L.; Neprašová, B.; Mengr, A.; Popelová, A.; Strnadová, V.; Holá, L.; Železná, B.; Kuneš, J.; Maletínská, L. Lipidized Prolactin-Releasing Peptide as a New Potential Tool to Treat Obesity and Type 2 Diabetes Mellitus: Preclinical Studies in Rodent Models, Front. Pharmacol. 2021, 12, 779962. https://doi.org/10.3389/fphar.2021.779962
